Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial

<table>Results of induction of IFN-<i>γ</i> secreting T lymphocytes detected by ELISPOT in response to autologous tumors cells after DC-based immunotherapy for melanoma.  Peripheral blood lymphocytes collected (PBMC) at week 0 (open bars) and week 4 (filled bars) were coincubated with purified autologous tumor cells at a ratio of 1 : 2, respectively, and incubated for 48 hours.  Data shown is sorted by average number of spots/100 K PMBC ± SD.  Dashed line approximates the 5 spots/100 K PBMC threshold.</table>

BioMed Research International

fig2

Figure 2

Figure 2: Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial 

Figure 2 | Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial 